PROADAPT-ovary/EWOC-2

With the conjunction of increased life expectancy and the increasing incidence of cancer with aging, older patient represent an increasing proportion of cancer patients. Increasing age is also associated with increased risk of co-morbidities as well as a decline of functional reserve of multiple organ systems, eventually leading in the context of the disease-and/or the treatment-related stress to functional deconditioning or organ failure.

Surgery or complex medico-surgical procedures can be considered as one proof-of principle of such risks, since major cancer surgery the older population is at higher risk of morbi-mortality and unplanned hospitalization for geriatric events1.

In order to reduce complications after surgery, prehabilitation has often been considered, and 71% of the surgeons would accept a 4 weeks delay before surgery to improve patients' outcomes if shown to be beneficial2. However, the actual level of evidence depends on the interventions: high for pre-operative nutrition3, but low for physical exercise, due to heterogeneous programs with often bad adherence4. In addition, geriatric validated interventions, in order to prevent iatrogenic event, may be added in a multi-interventional model of intervention.

Inclusion criteria

• Woman ≥70 year old OR Woman ≥60 years with significant comorbid condition (modified Charlson index≥3) or disability (ADL score<6/6);
• Histologically or cytologically proven FIGO (International Federation of Gynecology and Obstetrics) stage III to IV epithelial ovarian cancer or peritoneal primary or fallopian tube. A cytological proof is accepted if associated with a ratio of CA125/CEA >25 and a radiological pelvic mass.
• Patient oriented towards a complex medical procedure defined by pelvic surgery preceded or not by antineoplastic treatment (neoadjuvant chemotherapy).
• Therapeutic decision validated in a multidisciplinary consultation meeting
• Life expectancy > 3 months.
• Written informed consent obtained.
• Covered by a Health System where applicable.

Exclusion criteria

• Any other progressive malignant tumor interfering with the patient's prognosis.
• Patient whose validated therapeutic management does not include cytoreductive surgery.
• Patient unable to be regularly followed up for any reason (geographic, family, social, psychological).
• Patient unable to understand the questionnaires.
• Patient unable to follow and adhere to test procedures for geographic, social or psychological reasons.
• Patient placed under guardianship or curatorship.
• Patient deprived of liberty.
• Concurrent participation in another interventional drug trial.
• Patient already included in this study